Yes we have to remember how complicated designing trials are. With limited data and knowledge, you have to devise the protocols for treatment (how much? how often? how delivered? what kind of patient? what stage of disease? etc, etc......) And if something isn't right, it can tank the trial, and the company. Been known to happen ;)